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Estimated and Projected World Cancer Incidence by Selected Types of Cancer 
Source: US Census Bureau , NCI, WHO
Estimated and Projected World Cancer Mortality by Selected Types of Cancer 
Cancer Incidence (in thousands)
Year Lung Breast Colon Stomach Liver Prostate Cervical Esophageal Lymphoma Pancreatic Melanoma
2005 1 352 1 200 1 025 935 627 680 492 463 364 233 160
2020 1 700 1 400 1 300 1 150 680 1 280 530 480 380 264 177
Percent Change (2005-2020)
1,5 % 1,0 % 1,6 % 1,4 % 0,5 % 4,3 % 0,5 % 0,2 % 0,3 % 0,8 % 0,7 %
Cancer Mortality (in thousands)
Year Lung Breast Colon Stomach Liver Prostate Cervical Esophageal Lymphoma Pancreatic Melanoma
2005 1 180 410 529 700 598 222 274 386 195 227 41
2020 1 100 400 620 730 632 245 190 395 200 243 43
Percent Change (2005-2020)
-0,5 % -0,2 % 1,1 % 0,3 % 0,4 % 0,7 % -2,4 % 0,2 % 0,2 % 0,5 % 0,3 %
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Cancer remains as an unmet medical need      
Localization Incidence Mortality
Lung cancer 4 378 5 051
Prostate Cancer 2 527 2 509
Breast cancer 2 496 1 357
Colon cancer 1 683 1 869
Cervical cancer 1 271 457
New  Cases of Cancer (2006) and Mortality (2008) in Cuba (greatest frequency types)
Source: National Cancer  Registry and Department of Statistics. Cuban Health Ministry
FDA Approves Prostate Cancer Treatment
NBC Nightly News (4/29, story 3, 2:00, Williams) reported that "the FDA has approved" 
Provenge (sipuleucel-T), "a vaccine for prostate cancer.
In 4 weeks
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Anti-EGF Ab blocks  the 
EGF/EGFR binding














































ITT (OS) Younger than 60 (OS)
NSCLC: The EGF-P64 Vaccine  
Randomized POC Phase II CT in 80 NSCLC patients











































- Initially reported by us in human breast tumours in the early ninethies
- Also expressed in other types of cancers: NSCLC, Colon, Stomach, Ovarian, Melanomas etc
- Almost absent in human normal tissues
- A potent immunosuppressor, mainly for CD4+ T cells
- Available from horse erythrocytes and fully synthetic 
NSCLC: Racotumomab (1E10) Idiotypic Vaccine 
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Vaccine formulation: 1E10 mAb in Al(OH)3
C MI
NSCLC: Racotumomab (1E10) Idiotypic Vaccine  
Randomized POC Phase II CT in 174 NSCLC patients
Interim analysis  at  81 events
Starting a Multinational Phase III pivotal trial in 1 084 NSCLC patients  
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Very Small Sized Proteoliposomes: the Common  Fact 

















Statistics Graph (1 measurements)
Mean with Max-Min error bar
Size: 24,7 ± 1,1 nm
Zeta potential: - 25.5 ± 2.54 mV




























Very Small Sized Proteoliposomes: the Common  Fact 
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Breast Cancer: The GlycovaxGM3 Vaccine




















Randomized POC Phase II CT in 79 MBC patients
Survival Analysis for Non Visceral Patients (ITT, n = 50/79)
+   Montanide  ISA 51
NGcGM3
Currently ongoing two Phase III pivotal trials, one in 776 MBC patients, other









Median 26,17 12,17 0,269 0,049
+
Biochemical and Immunological Findings   
Clinical Update 
- 5 patients with normalized prostate gland
- 1 patient with grade I prostate gland
HeberProvac
- Synthetic peptide GnRHm1-TT (3mg)
- VSSP (245 µg)
- Montanide ISA-51 (350 µL)
Phase I Study:  8 hormone-sensitive metastatic prostate cancer patients 
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HeberProvac might be an innovative solution for prostate cancer       


























































































PSA (ng/ml) Testosterone (nmol/L) x 10
Castration level (1.7 nmol/L) x 10 Immunizations
1rst Evaluation Final evaluation
Anti-GnRH titres
POC Phase II study starting in 2010
CIGB 228: HPV E7 peptide for HLA-A*02 restricción in VSSP,  SC injection 
☼ 7 patients with High Grade Cervical Dysplasia / HPV 16/ HLA-A*02 , 4 doses of the vaccine
☼ End points: safety, colposcopy and histopathologic analysis, immunogenicity
- The vaccine was safe and well tolerated 
- High-grade cervical dysplasias were resolved in 57% of patients
- Partial responses were obtained in 29% of patients
- Complete and partial responses observed  in 86% of cases
Phase I Clinical trial 
POC Phase II study starting in 2010
Patient No Colposcopy Histology Immunogenicity 
01 CR CR +++
02 SD SD ++
03 PR PR ++
04 CR CR +++
05 CR CR ++
06 CR CR +++
07 SD SD +




• Eight innovative therapeutic cancer vaccines are in development in Cuba
as a consequence of the existence of the Cuban Biotech System
• Vaccine candidates are focused in the more frequent types of cancer
affecting people in Cuba
• VSSP vaccine technology is the common fact present in the majority of
these projects
Thanks for your attention¡¡
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